undamentalytics Newsletter
Sign in

Viridian Therapeutics, Inc.\de income statement

In fiscal 2025, Viridian Therapeutics, Inc.\de reported revenue of $70.8m, up 23359.9% on the year before, operating income of −$363m (a -512.9% margin) and net income of −$343m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue5663484132007171
Cost of revenue3323——————————
Gross profit3331——————————
Research and development001142030352857101160238339325
Selling, general and administrative——————————956195—
Selling and marketing0132——————————
General and administrative1787111112132635————
Operating income−0−7−11−17−27−33−42−110−80−134−254−299−363−405
Interest expense2100—————112516
Income tax—00—————————0—
Net income−2−8−11−17−27−33−42−111−79−130−238−270−343−387
Diluted EPS−$2751.75−$787.50−$315.30−$423.15−$20.70−$16.50−$20.04−$31.13−$6.66−$4.05−$5.31———
Diluted shares (average)————1m2m2m4m12m32m45m———
EBITDA−0−7−11−17−26−33−42−110−80−134−254−298−363−405

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: VRDN vs WVECGEN vs VRDNRXRX vs VRDNASMB vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viridian Therapeutics, Inc.\de's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viridian Therapeutics, Inc.\de.